title: Deferoxamine retinopathy: spectral domain-optical coherence tomography findings.
abstract: BACKGROUND
  To describe the spectral domain optical coherence tomography (SD-OCT) findings of a patient who developed pigmentary retinopathy following high-dose deferoxamine administration.
  
  
  METHODS
  A 34-year-old man with thalassemia major complained of nyctalopia and decreased vision following high-dose intravenous deferoxamine to treat systemic iron overload. Fundus examination revealed multiple discrete hypo-pigmented lesions at the posterior pole and mid-peripheral retina. Recovery was partial following cessation of desferrioxamine six weeks later. A follow-up SD-OCT showed multiple accumulated hyper-reflective deposits primarily in the choroid, retina pigment epithelium (RPE), and inner segment and outer segment (IS/OS) junction.
  
  
  CONCLUSIONS
  Deferoxamine retinopathy primarily targets the RPE-Bruch membrane-photoreceptor complex, extending from the peri-fovea to the peripheral retina with foveola sparing. An SD-OCT examination can serve as a simple, noninvasive tool for early detection and long-term follow-up.
authors.forename: Cheng-Hsiu
authors.initials: CH
authors.lastname: Wu
authors.forename: Chao-Ping
authors.initials: CP
authors.lastname: Yang
authors.forename: Chi-Chun
authors.initials: CC
authors.lastname: Lai
authors.forename: Wei-Chi
authors.initials: WC
authors.lastname: Wu
authors.affiliation: Department of Ophthalmology, Chang Gung Memorial Hospital, No, 5, Fu-Hsing Street, Kweishan, Taoyuan 333, Taiwan. yihsing@gmail.com.
authors.forename: Yi-Hsing
authors.initials: YH
authors.lastname: Chen
mesh_terms: D000328:Adult; D003676:Deferoxamine / Q000008:administration & dosage / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D005451:Fluorescein Angiography; D005654:Fundus Oculi; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D012164:Retinal Diseases / Q000139:chemically induced / Q000175:diagnosis*; D055213:Retinal Pigment Epithelium / Q000187:drug effects / Q000473:pathology*; D017262:Siderophores / Q000008:administration & dosage / Q000009:adverse effects; D013789:Thalassemia / Q000188:drug therapy; D041623:Tomography, Optical Coherence / Q000379:methods*; D014792:Visual Acuity
chemical_list: D017262:Siderophores; D003676:Deferoxamine